As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Monogram Technologies Inc. The largest reported stake is Zimmer Biomet Holdings, Inc.'s, at 27%. 2 filings are on record since July 15, 2025 (Schedule 13D, July 15, 2025).
Sell to companies like Monogram Technologies Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Monogram Technologies Inc. has 2 Schedule 13D or 13G filings on record since 2025-07-15. 2 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Zimmer Biomet Holdings, Inc. | 27% | 9,754,256 | SCHEDULE 13D, 2025-07-15 | 2025-07-11 |
| 5.8% | 2,360,304 | SCHEDULE 13G, 2025-07-18 | 2023-12-31 |
Holding shares or following this stake? See who's behind Monogram Technologies Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Monogram Technologies Inc. and the records around it.
Monogram Technologies Inc. elsewhere on the record
- Acquisition Oct 2025
Watch Monogram Technologies Inc.
Get an email when Monogram Technologies Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Monogram Technologies Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Monogram Technologies Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Monogram Technologies Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Zimmer Biomet Holdings, Inc.
The purpose of the Merger (as defined below) is for Parent, through Merger Sub, to acquire control of, and the entire equity interest in, the Company. On July 11, 2025, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement") with Parent and Merger Sub. The Board of Directors of the Company (the "Board") has unanimously approved the Merger Agreement and the transactions contemplated thereby, including the Merger. Effect on Capital Stock The Merger Agreement provides that, subject to the terms and conditions set forth therein, at the effective time of the Merger (the "Effective Time"), (1) Merger Sub will be merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation and a wholly-owned subsidiary of Parent, (2) each share of Common Stock issued and outstanding immediately prior to the Effective Time (other than shares owned by (i) the Company (or held in the Company's treasury), (ii) Parent, Merger Sub or any other direct or indirect wholly-owned subsidiary of Parent or Merger Sub or (iii) stockholders who have properly exercised and perfected appraisal rights under Delaware law) will be automatically cancelled and converted into the right to receive (A) $4.04 per share in cash, without interest and subject to applicable withholding taxes (the "Cash Amount"), plus (B) one contractual contingent value right per share representing the right to receive five contingent cash …The first part of Item 4 of the SCHEDULE 13D filed 2025-07-15; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-15 | Zimmer Biomet Holdings, Inc. | 27% | SCHEDULE 13D |
| 2025-07-18 | Icahn School Of Medicine At Mount Sinai | 5.8% | SCHEDULE 13G |
Questions about who owns Monogram Technologies Inc.
Who owns Monogram Technologies Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Monogram Technologies Inc.: Zimmer Biomet Holdings, Inc. (27%, Schedule 13D, filed 2025-07-15) and Icahn School Of Medicine At Mount Sinai (5.8%, Schedule 13G, filed 2025-07-18).
Who are the largest shareholders of Monogram Technologies Inc.?
By the share each holder's latest filing reports, the largest holders of Monogram Technologies Inc. on this page are Zimmer Biomet Holdings, Inc. (27%) and Icahn School Of Medicine At Mount Sinai (5.8%).
When did Zimmer Biomet Holdings, Inc. buy into Monogram Technologies Inc.?
The filings give report dates, not purchase dates. The earliest filing from Zimmer Biomet Holdings, Inc. on this page is the Schedule 13D, filed 2025-07-15, reporting 27%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Monogram Technologies Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| January 1, 2026 | Acquired by Zimmer Biomet | — | Acquisition | Source |
Tools for this story
Each opens in a new tab, filled in for Monogram Technologies Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.